TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03262766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia (AIH)
Description: This will consist of up to 90 seconds of 9-10% O2 (FiO2 0.09), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute Intermittent Hypoxia (AIH)
Description: This will consist of up to 90 seconds of 9-10% O2 (FiO2 0.09), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upper extremity training
Description: Subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®. Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs. It cradles the entire arm, from shoulder to the hand, and counterbalances the weight of the user's arm. Therefore, it enhances any residual function and neuromuscular control, and assists in active movement across a large 3-D workspace. The Armeo software contains an extensive library of game-like movement exercises supported by a virtual-reality training environment that displays the functional task along with immediate performance feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity training
Description: Subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®. Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs. It cradles the entire arm, from shoulder to the hand, and counterbalances the weight of the user's arm. Therefore, it enhances any residual function and neuromuscular control, and assists in active movement across a large 3-D workspace. The Armeo software contains an extensive library of game-like movement exercises supported by a virtual-reality training environment that displays the functional task along with immediate performance feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Acute intermittent hypoxia
Description: This will consist of up to 90 seconds of 21% O2 (FiO2 0.21), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of alternating normoxic air will be repeated up to 18 times per session each, for a total of up to 45 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acute intermittent hypoxia
Description: This will consist of up to 90 seconds of 21% O2 (FiO2 0.21), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of alternating normoxic air will be repeated up to 18 times per session each, for a total of up to 45 minutes.
Study: NCT03100916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517 (Reference)
Description: Fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: Non- fasting
Study: NCT00764387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadovist® (Gadobutrol, BAY86-4875)
Description: 0,1 mmol/kg of body weight in the vein, single administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dotarem
Description: 0,1 mmol/kg of body weight in the vein, single administration
Study: NCT02163967

Intervention type: DEVICE
Group type: OTHER
Intervention: Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)
Description: low voltage alternating current transcranial electrical stimulation

Intervention type: DEVICE
Group type: OTHER
Intervention: Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)
Description: low voltage alternating current transcranial electrical stimulation

Intervention type: DEVICE
Group type: OTHER
Intervention: Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)
Description: low voltage alternating current transcranial electrical stimulation

Intervention type: DEVICE
Group type: OTHER
Intervention: Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)
Description: low voltage alternating current transcranial electrical stimulation

Intervention type: DEVICE
Group type: OTHER
Intervention: Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)
Description: low voltage alternating current transcranial electrical stimulation

Intervention type: DEVICE
Group type: OTHER
Intervention: Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)
Description: low voltage alternating current transcranial electrical stimulation
Study: NCT01491386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS/LT-CAGE® Device
Description: LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous Bone/LT-CAGE® Device
Description: LT-CAGE® device with autogenous bone taken from the iliac crest.
Study: NCT01972308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Advocate
Description: Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to accomplishing medical advice, and transfer of information between provider and patient.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Subjects receive asthma care from their proivders in the participating practices which generally follow asthma guidelines
Study: NCT03585504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel contraceptive implant
Description: Etonogestrel contraceptive implant
Study: NCT03691844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMZ001
Description: diclofenac gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMZ001
Description: diclofenac gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00949117

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PediaSure
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyproheptadine hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyproheptadine hydrochloride
Description: Given orally
Study: NCT01419808

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vascularized Bone Graft
Description: Vascularized bone graft in the treatment of Scaphoid Non-Union

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Vascularized Bone Graft
Description: Non-Vascularized Bone Graft in the treatment of Scaphoid Non-unions
Study: NCT03585504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel contraceptive implant
Description: Etonogestrel contraceptive implant
Study: NCT00360269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 25 to 100 mg daily

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Description: Three sessions

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Motivational enhancement therapy
Description: Three sessions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 to 100 mg daily
Study: NCT01818180

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: URELL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02824926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapaconazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Study: NCT03792061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy Training
Description: This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
Study: NCT02029443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Participants will receive acalabrutinib as stated in the arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Participants will receive acalabrutinib as stated in the arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Participants will receive acalabrutinib as stated in the arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Participants will receive acalabrutinib as stated in the arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Participants will receive acalabrutinib as stated in the arms' description.
Study: NCT03691844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: diclofenac gel
Study: NCT00883012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent sub-unit influenza vaccine
Description: Composition per 0.5 ml dose:~Active substance:~Split Influenza virus\*, inactivated Strains for 2009 Southern hemisphere A/Brisbane/59/2007- like (H1N1) 15 micrograms\*\*, A/Brisbane/10/2007 (H3N2) - like strain (A/Brisbane/10/2007 (IVR-147) 15 micrograms\*\*, B/Florida/4/2006 - like strain (B/Brisbane/3/2007)15 micrograms\*\* Two doses, one month apart
Study: NCT04065399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: revumenib
Description: revumenib orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobicistat
Description: Phase 1 Arm C participants will receive 150 mg cobicistat daily.
Study: NCT00883012

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline, 0.5ml
Description: Saline IMI, 0.5ml. Two doses one month apart
Study: NCT00374569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gymnastic Routine
Description: A combination of gymnastic movements are performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gymnastic Routine
Description: A combination of gymnastic movements are performed
Study: NCT02275715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training Program
Description: An 11-session manualized behavioral parent training program for the treatment of feeding problems teaching parents to use a range of behavioral procedures to address a variety of common feeding problems.
Study: NCT00415428

Intervention type: BEHAVIORAL
Intervention: Patient adherence to national educational guidelines.
Study: NCT00707707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: Dose finding study to establish the appropriate dose of AZD2281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous infusion over 1 hour
Study: NCT00105482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine replacement
Description: Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
Study: NCT02789423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Pulp Capping using Dycal and Biodentine
Description: The operative procedure performed as follows: i)Administration of L.A and rubber dam isolation. ii)High-speed carious enamel removal. iii)Dentine mechanical curettage. iv)Manual final dentine curettage using a spoon excavator. v)Hemorrhage control by cotton pellet moistened with 2.5% sodium hypochlorite placed over the exposure for 1-2min. vi)The exposure site would then be dried with sterile cotton pellet.The operator shall apply the pulp capping agent(dycal/Biodentine)according to the manufacturer's instructions.And then another cover of glass ionomer is applied.This would be followed by permanent restoration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Pulp Capping using Dycal and Biodentine
Description: The operative procedure performed as follows: i)Administration of L.A and rubber dam isolation. ii)High-speed carious enamel removal. iii)Dentine mechanical curettage. iv)Manual final dentine curettage using a spoon excavator. v)Hemorrhage control by cotton pellet moistened with 2.5% sodium hypochlorite placed over the exposure for 1-2min. vi)The exposure site would then be dried with sterile cotton pellet.The operator shall apply the pulp capping agent(dycal/Biodentine)according to the manufacturer's instructions.And then another cover of glass ionomer is applied.This would be followed by permanent restoration.
Study: NCT00418652

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: No TMS intervention
Description: In the no TMS condition, no simulation was given and no coil placed near participants' heads.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS over the PO3 EEG site
Description: 10Hz TMS over the dorsal stream (PO3 EEG site)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS over the vertex
Description: 10Hz TMS for over vertex.
Study: NCT00715351

Intervention type: DRUG
Intervention: insulin detemir
Description: Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician

Intervention type: DRUG
Intervention: insulin NPH
Description: Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
Study: NCT04547907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel+ trastuzumab+ patuzumab
Description: Nab-paclitaxel 125mg/m2 (days 1, 8, 15) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel+ carboplatin+ trastuzumab + patuzumab
Description: Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
Study: NCT04372147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MMA embolization
Description: Patients in the intervention group will undergo a CT angiography scan of the supra aortic trunks, followed by MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care
Study: NCT02639169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: apply live music through the techniques of music therapy
Study: NCT03957499

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone/bupivacaine
Description: Ultrasound guided fascia iliaca compartment block (FICB) will be performed with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml)d using

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate/bupivacaine
Description: Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
Study: NCT02387905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of Therapy Complications
Description: Undergo vertebral body cement augmentation
Study: NCT00105482

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal nicotine replacement
Description: Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Description: Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral counseling
Description: Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.
Study: NCT00380757

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bystander CPR using 30:2 ratio vs 15:2 ratio
Description: Participants will use 2 CPR techniques with different chest compression to ventilation ratios

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bystander CPR using 30:2 ratio vs 15:2 ratio
Description: Participants will use 2 CPR techniques with different chest compression to ventilation ratios
Study: NCT03606733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Custom suorachoroidal needle
Description: Custom made Supra Choroidal Space needle
Study: NCT01812824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (Virtual Patient Advocate)
Description: Intervention (Virtual Patient Advocate) participants will have access to the Gabby system for 6 months. There is no required dose or frequency that they have to log on to the system, but the investigators will suggest that they log on once a week.
Study: NCT02387905

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02170051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBSST-CCT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal focused supportive contact
Study: NCT00038857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Megadose of CD34 Selected Progenitor Cells
Description: Haploidentical peripheral blood progenitor cell (PBPC) transplants on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 on day -8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 10 mg/kg on day -7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 160 mg/m\^2 over 4 days on days -6, -5, -4, -3
Study: NCT02387905

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo standard stereotactic spinal radiosurgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo standard stereotactic spinal radiosurgery
Study: NCT01535599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-60371, 0.3% Otic Suspension

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AL-60371 Vehicle
Description: Inactive ingredients used as a placebo comparator
Study: NCT01467050

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of STOPP/START criteria
Description: The researcher will apply the STOPP/START criteria to the cases randomised to this intervention. This will occur at the point of recruitment into the study and consists of applying STOPP/START criteria to the list of prescribed medications the patient is taking at that time point.~Where potentially inappropriate medications (PIM's) are identified using the intervention, these are highlighted to the medical team with primary responsibility for the patient both verbally and in writing. The relevant registrar will be contacted in person or via telephone by the researcher and informed of the PIM's in addition to a standard medication advice form inserted into the patients' notes also highlighting the PIM's.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Normal pharmaceutical care
Description: The normal process of medication prescription and review by the attending medical team.
Study: NCT03179254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin continue
Description: Oral hypoglycemic agent continue on the day of ambulatory surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin discontinue
Description: Oral hypoglycemic agent discontinue on the day of ambulatory surgery
Study: NCT01528891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 0.5 micrograms/Kilogram one time bolus 5 minutes prior to the end of surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03800446

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Point of care ferritin test
Description: Point of care test that uses capillary blood sample from finger to determine ferritin level
Study: NCT01940250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: MgSO4 IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: H2O IV infusion
Study: NCT02135029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: 150 mg every 2 weeks by subcutaneous injection for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin PO QD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Bococizumab (PF-04950615;RN316)
Description: 150 mg every 2 weeks by subcutaneous injection for 24 weeks
Study: NCT00038857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Description: 1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
Study: NCT02135029

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for atorvastatin
Description: PO QD